The introduction of immunotherapy, including anti-CD19 and anti-CD22 therapies, has further emphasized the need to differentiate typical Ph+ ALL from CML-like cases to optimize treatment strategies in future protocols [33,34]. The gene discussed is CD19; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.